Evidence map›Paper›PMID 26746195›Full record

Trial reportTrials2016

Comparative effectiveness of antihypertensive treatment for older children with primary hypertension: study protocol for a series of n-of-1 randomized trials.

Joyce P Samuel, Joshua A Samuels, Lauren E Brooks, Cynthia S Bell, Claudia Pedroza, Donald A Molony, Jon E Tyson

2 registry-linked trialsOpen access · goldAbstract readComparative StudyRandomized Controlled Trial
In one paragraph

Trial report in Trials, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02412761 nacompletednot on this map

Series of N-of-1 Crossover Trials of Antihypertensive Therapy in Adolescents With Essential Hypertension

TypeinterventionalSponsorThe University of Texas Health Science Center, HoustonRan2013 to 2016Enrolled42ConditionsEssential HypertensionArmsLisinopril, Amlodipine, Hydrochlorothiazide
NCT04752293 recruitingnot on this mapstarted 2021, after this paper: background citation

Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE): The Role of Angiotensin-(1-7) in Hypertension and Hypertension-Induced Heart and Kidney Damage

TypeobservationalSponsorWake Forest University Health SciencesRan2021 to 2026Enrolled125ConditionsHypertension, Left Ventricular Hypertrophy, Left Ventricular Dysfunction, Left Atrial Dilatation
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 12 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Joyce P SamuelDivision of Pediatric Nephrology and Hypertension, University of Texas Health Science Center at Houston (UTHealth) McGovern Medical School, 6431 Fannin, MSB 3.121, Houston, Texas, 77030, USA. joyce.p.samuel@uth.tmc.edu.
Joshua A SamuelsDivision of Pediatric Nephrology and Hypertension, University of Texas Health Science Center at Houston (UTHealth) McGovern Medical School, 6431 Fannin, MSB 3.121, Houston, Texas, 77030, USA. Joshua.A.Samuels@uth.tmc.edu.
Lauren E BrooksUTHealth McGovern Medical School, Houston, Texas, USA. Lauren.E.Brooks@uth.tmc.edu.
Cynthia S BellDivision of Pediatric Nephrology and Hypertension, University of Texas Health Science Center at Houston (UTHealth) McGovern Medical School, 6431 Fannin, MSB 3.121, Houston, Texas, 77030, USA. Cynthia.Bell@uth.tmc.edu.
Claudia PedrozaDivision of Pediatric Nephrology and Hypertension, University of Texas Health Science Center at Houston (UTHealth) McGovern Medical School, 6431 Fannin, MSB 3.121, Houston, Texas, 77030, USA. Claudia.Pedroza@uth.tmc.edu.
Donald A MolonyDivision of Renal Diseases and Hypertension, UTHealth McGovern Medical School, Houston, Texas, USA. Donald.A.Molony@uth.tmc.edu.
Jon E TysonDivision of Pediatric Nephrology and Hypertension, University of Texas Health Science Center at Houston (UTHealth) McGovern Medical School, 6431 Fannin, MSB 3.121, Houston, Texas, 77030, USA. Jon.E.Tyson@uth.tmc.edu.
The University of Texas Health Science Center at Houston · US

Funding

Center for Clinical and Translational Sciences (CCTS)UL1TR000371 · NCATS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MCPHERSON, DAVID D · 2012 to 2016
$13.4M
Center for Clinical and Translational Sciences (CCTS)KL2TR000370 · NCATS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MCPHERSON, DAVID D · 2012 to 2016
$4.3M
NCATS NIH HHS 5KL2 TR000370NCATS NIH HHS KL2 TR000370NCATS NIH HHS UL1 TR000371
6 · The paper itself

Abstract

backgroundChildren are increasingly being diagnosed with primary hypertension. The absence of comparative effectiveness research of antihypertensive medications in children has contributed to considerable differences in prescribing practices among physicians treating children with primary hypertension. Even if parallel-group trials had established a best overall choice for most of these children, the best medication for an individual may differ from the best overall medication. METHODS/

designThis project consists of a series of systematically administered n-of-1 trials among older children to verify the need for ongoing antihypertensive treatment and, if so, to identify the preferred single drug therapy from among the three major classes of drugs commonly used for primary hypertension (angiotensin-converting enzyme inhibitors, calcium channel blockers, and diuretics). We will determine whether one of these is the preferred therapy for the great majority of patients. The "preferred" therapy is the drug which produces normal ambulatory blood pressure, with the greatest reduction in blood pressure without unacceptable side effects. We will recruit 50 patients from the Houston Pediatric and Adolescent Hypertension Program clinic. For each patient, the three drugs will be prescribed in random order and each drug will be taken for 2 weeks. The effectiveness of each therapy will be measured with 24-h ambulatory blood pressure monitoring, and tolerability will be assessed using a side effect questionnaire. Participants will rotate through treatment periods, repeating drugs and adjusting doses until the preferred therapy is identified. In assessing whether one of the medications is most effective for the majority of subjects, the primary outcome will be the percentage of participants for whom each drug is selected as the preferred therapy. We hypothesize that no drug will be selected for the great majority of the subjects, a finding that would support consideration of clinical use of n-of-1 trials. Secondary analyses will explore whether patient characteristics predict which medication will be selected as a preferred drug. DISCUSSION: This study will help optimize care of participating patients and provide evidence regarding the usefulness of n-of-1 trials in identifying appropriate treatment for children with hypertension and potentially other disorders.

trial registrationClinicaltrials.gov NCT02412761 (registered 4/8/2015).

Indexed as

Clinical ProtocolsAdolescentAdultAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBlood Pressure Monitoring, AmbulatoryCalcium Channel BlockersChildDiureticsFemaleHumansHypertensionMaleAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsCalcium Channel BlockersDiuretics

Identifiers

PMID26746195
PMCPMC4706696
OpenAlexW2232224821

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.